These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22064379)

  • 1. Conversion of a murine monoclonal antibody A13 targeting epidermal growth factor receptor to a human monoclonal antibody by guided selection.
    Chang KH; Kim MS; Hong GW; Shin YN; Kim SH
    Exp Mol Med; 2012 Jan; 44(1):52-9. PubMed ID: 22064379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
    Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
    J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affinity Maturation of an Epidermal Growth Factor Receptor Targeting Human Monoclonal Antibody ER414 by CDR Mutation.
    Chang KH; Kim MS; Hong GW; Seo MS; Shin YN; Kim SH
    Immune Netw; 2012 Aug; 12(4):155-64. PubMed ID: 23091439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
    Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
    Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective therapeutic approach for head and neck cancer by an engineered minibody targeting the EGFR receptor.
    Kim YP; Park D; Kim JJ; Chi WJ; Lee SH; Lee SY; Kim S; Chung JM; Jeon J; Lee BD; Shin JH; Lee YI; Cho H; Lee JM; Kang HC
    PLoS One; 2014; 9(12):e113442. PubMed ID: 25438047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro.
    Yi CH; Ruan CP; Wang H; Xu XY; Zhao YP; Fang M; Ji J; Gu X; Gao CF
    Acta Pharmacol Sin; 2014 Nov; 35(11):1439-46. PubMed ID: 25263334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.
    Johns TG; Stockert E; Ritter G; Jungbluth AA; Huang HJ; Cavenee WK; Smyth FE; Hall CM; Watson N; Nice EC; Gullick WJ; Old LJ; Burgess AW; Scott AM
    Int J Cancer; 2002 Mar; 98(3):398-408. PubMed ID: 11920591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.
    Johns TG; Adams TE; Cochran JR; Hall NE; Hoyne PA; Olsen MJ; Kim YS; Rothacker J; Nice EC; Walker F; Ritter G; Jungbluth AA; Old LJ; Ward CW; Burgess AW; Wittrup KD; Scott AM
    J Biol Chem; 2004 Jul; 279(29):30375-84. PubMed ID: 15075331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor efficacy of an anti-epidermal-growth-factor-receptor monoclonal antibody and its F(ab')2 fragment against high- and low-EGFR-expressing carcinomas in nude mice.
    Tosi E; Valota O; Negri DR; Adobati E; Mazzoni A; Meazza R; Ferrini S; Colnaghi MI; Canevari S
    Int J Cancer; 1995 Sep; 62(5):643-50. PubMed ID: 7665239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling.
    Boersma YL; Chao G; Steiner D; Wittrup KD; Plückthun A
    J Biol Chem; 2011 Dec; 286(48):41273-41285. PubMed ID: 21979953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.
    Donaldson JM; Kari C; Fragoso RC; Rodeck U; Williams JC
    Cancer Biol Ther; 2009 Nov; 8(22):2147-52. PubMed ID: 19783899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.
    Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG
    Crit Rev Oncol Hematol; 2001 Apr; 38(1):17-23. PubMed ID: 11255078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Affinity maturation and fine functional mapping of an antibody fragment against a novel neutralizing epitope on human vascular endothelial growth factor.
    Lamdan H; Gavilondo JV; Muñoz Y; Pupo A; Huerta V; Musacchio A; Pérez L; Ayala M; Rojas G; Balint RF; Larrick JW
    Mol Biosyst; 2013 Aug; 9(8):2097-106. PubMed ID: 23702826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of humanized scFv antibody fragment(s) that targets and blocks specific HLA alleles linked to myasthenia gravis.
    Ayyar BV; Atassi MZ
    Appl Microbiol Biotechnol; 2017 Nov; 101(22):8165-8179. PubMed ID: 29034433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.
    Müller N; Hartmann C; Genssler S; Koch J; Kinner A; Grez M; Wels WS
    Int J Cancer; 2014 Jun; 134(11):2547-59. PubMed ID: 24243620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of humanized single-chain fragment variable immunotherapeutic against EGFR variant III using baculovirus expression system and in vitro validation.
    Xavier S; Gopi Mohan C; Nair S; Menon KN; Vijayachandran LS
    Int J Biol Macromol; 2019 Mar; 124():17-24. PubMed ID: 30471391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.
    Zhou Y; Goenaga AL; Harms BD; Zou H; Lou J; Conrad F; Adams GP; Schoeberl B; Nielsen UB; Marks JD
    Mol Cancer Ther; 2012 Jul; 11(7):1467-76. PubMed ID: 22564724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, expression and evaluation of a novel humanized single chain antibody against epidermal growth factor receptor (EGFR).
    Akbari B; Farajnia S; Zarghami N; Mahdieh N; Rahmati M; Khosroshahi SA; Rahbarnia L
    Protein Expr Purif; 2016 Nov; 127():8-15. PubMed ID: 27298212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy.
    Bleeker WK; Lammerts van Bueren JJ; van Ojik HH; Gerritsen AF; Pluyter M; Houtkamp M; Halk E; Goldstein J; Schuurman J; van Dijk MA; van de Winkel JG; Parren PW
    J Immunol; 2004 Oct; 173(7):4699-707. PubMed ID: 15383606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.